Ceftriaxone & Tazobactam Injection 281.25 mg Supplier for Washington, USA

Quality Injectable Antibiotic from Ernest Oncology

Ernest Oncology is an Indian pharmaceutical exporter supplying Ceftriaxone & Tazobactam Injection 281.25 mg for international healthcare markets, including Washington, USA. Manufactured under strict quality standards, this sterile injectable formulation combines Ceftriaxone 250 mg and Tazobactam 31.25 mg to provide enhanced antibacterial coverage against susceptible microorganisms when administered by qualified healthcare professionals.

Washington Pharmaceutical Market

Washington continues to experience growing demand for reliable injectable antibiotics due to its advanced hospitals, healthcare facilities, specialty clinics, and expanding medical services. Healthcare providers prioritize pharmaceutical products manufactured according to internationally recognized quality standards with dependable product consistency.

Indian pharmaceutical manufacturers remain trusted globally for producing affordable, high-quality injectable medicines supported by modern manufacturing technologies.

Why Choose Indian Pharmaceutical Exports

India is one of the world's largest pharmaceutical manufacturing hubs, supplying medicines to healthcare systems across more than 200 countries.

Advantages include

• WHO-GMP certified production facilities
• International quality standards
• Modern pharmaceutical manufacturing
• Competitive production capabilities
• Reliable medicine availability
• Experienced export infrastructure
• Secure packaging systems
• Global distribution network
• Comprehensive documentation
• Continuous quality monitoring

Product Overview

Key Features

• Dual antibacterial formulation
• Ceftriaxone with Tazobactam combination
• Sterile injectable preparation
• WHO-GMP manufactured
• Export-quality packaging
• Stable pharmaceutical formulation
• High manufacturing consistency
• International quality compliance
• Suitable for hospital use
• Reliable shelf stability

Product Description

Ceftriaxone & Tazobactam Injection 281.25 mg is a sterile injectable antibiotic containing Ceftriaxone 250 mg and Tazobactam 31.25 mg. The combination is prescribed by healthcare professionals for the management of susceptible bacterial infections where enhanced antibacterial protection is required.

The injection is intended for intramuscular (IM) or intravenous (IV) administration under professional medical supervision.

Mechanism of Action

This combination medicine works through complementary antibacterial mechanisms.

• Ceftriaxone inhibits bacterial cell wall synthesis, resulting in bacterial cell death.
• Tazobactam inhibits beta-lactamase enzymes produced by certain bacteria, helping preserve Ceftriaxone's antibacterial activity.

Together they provide broader antibacterial effectiveness against susceptible pathogens.

Side Effects

Possible side effects include:

• Pain at injection site
• Nausea
• Vomiting
• Diarrhea
• Headache
• Skin rash
• Dizziness
• Fever
• Allergic reactions
• Temporary liver enzyme changes

Seek medical advice if symptoms persist or worsen.

Safety Information

• Prescription-only medicine.
• Use only under medical supervision.
• Inform your doctor about allergies before treatment.
• Complete the prescribed antibiotic course.
• Follow physician instructions carefully.
• Keep away from children.
• Do not use after expiry.

Storage Information

• Store below 25°C
• Protect from moisture
• Keep away from sunlight
• Store in original packaging
• Do not freeze
• Use before expiry date

Quality Assurance

Every batch supplied by Ernest Oncology is sourced from manufacturers operating under internationally recognized pharmaceutical quality systems.

Quality Standards

• WHO-GMP manufacturing
• Batch quality inspection
• Sterile production environment
• Export-quality packaging
• Controlled storage
• Product traceability
• Documentation verification
• International quality compliance